Core Viewpoint - The company has disclosed that it is currently undergoing a review by the USPTO regarding the validity of a patent held by its subsidiary, which has been challenged by a related company, CSPC Baike. The outcome of this review may have implications for the company's intellectual property rights and ongoing drug development efforts [1][2]. Group 1 - The review initiated by CSPC Baike questions the validity of a patent held by the company's subsidiary, which is currently under examination by the USPTO [1][2]. - The compound in question, Compound 1, is identical to CSPC Baike's Compound 10, but the company's patent application was submitted over three months earlier than CSPC's [1]. - The company has expressed confidence in the validity of its patent and is prepared to take necessary legal actions to defend its intellectual property rights if the review proceeds [2]. Group 2 - The patent in question is based on proprietary technology developed by the company and is currently being utilized in the research and development of its candidate drug ASC30 [2]. - The USPTO granted the patent to the company's subsidiary on February 25, 2025, based on its novelty and non-obviousness compared to existing technologies [2]. - The company asserts that the ongoing review does not currently impact its business operations or overall group performance [2].

Core Viewpoint - The article discusses the ongoing patent dispute between Songlei and Conjupro Biotherapeutics, a subsidiary of CSPC Pharmaceutical Group, regarding the validity of a US patent held by Songlei, which is currently under review by the USPTO [1][3]. Group 1: Patent Dispute Details - On June 30, Songlei announced that it was informed on June 24 about Conjupro's request for a Post Grant Review at the USPTO, questioning the validity of specific claims in Songlei's US patent (Patent No: 12,234,236) [1]. - Conjupro's application for "Compound 10" is claimed to be structurally identical to Songlei's "Compound 1," with Songlei asserting that its patent application was submitted over three months prior to Conjupro's [1]. - As of the announcement, the review request is still under examination by the USPTO [1]. Group 2: Background and Implications - Songlei noted that it could not ascertain the specific reasons behind Conjupro's review request, but highlighted that Conjupro had previously sought global licensing discussions for the GLP-1R agonist Compound 1, which Songlei declined [3]. - The patent in question is based on proprietary technology developed by Songlei and is currently being utilized in the development of the candidate drug ASC30, with multiple related molecules protected under various patent systems [4]. - The USPTO officially granted the patent rights to Songlei on February 25, 2025, citing its innovation and non-obviousness compared to existing technologies [4].

该专利系利用歌礼专有技术开发而成，目前正应用于公司候选药物ASC30的研发。公司包括化合物1和 ASC30在内的化合物受多项专利保护，包括前述该专利。基于其与现有技术相比具有新颖性和非显而易 见性，USPTO已于2025年2月25日将该专利权授予公司附属公司歌礼制药(中国)有限公司。 公司对于该专利的有效性充满信心，如该复审继续推进，公司将采取一切必要的法律手段捍卫公司的知 识产权。 由于该复审目前仍在USPTO审查中，当前阶段该复审对集团无潜在影响。公司将密切关注该复审的进 展并评估其影响，与此同时，当前公司的业务及运营未受影响。 智通财经APP讯，歌礼制药-B(01672)发布公告，该公司董事会于2025年6月24日获悉由石药集团有限公 司(一家于香港联合交易所有限公司上市的公司，股份代号：1093)附属公司康久普乐生物医疗有限公司 (Conjupro Biotherapeutics, Inc.)向美国专利商标局(USPTO)提交的一项复审。该复审质疑公司附属公司歌 礼制药(中国)有限公司一项已获授权的美国专利(美国专利号：12,234,236)权利要求 1-9、12-17及21-25 的有效性。截至本公 ...